Edinburgh Postnatal Depression Scale (EPDS) (also searched as Cox's postnatal depression scale, Edinburgh scale, ICD-10: F53.0, Z13.89) is a widely validated, 10-item self-administered psychometric instrument specifically developed to detect perinatal depressive and anxiety symptoms in pregnant and postpartum women^{1, 2}. Originally devised by J.L. Cox, J.M. Holden, and R. Sagovsky in 1987, the scale addresses the diagnostic challenge of differentiating normative physical symptoms of pregnancy and early motherhood—such as fatigue, sleep disturbance, and appetite changes—from pathological affective disruption^{1, 6}. Each item is scored on a 4-point scale ranging from 0 to 3, yielding a total composite score between 0 and 30¹. By emphasizing cognitive appraisal, anhedonia, guilt, and anxiety, the EPDS serves as an essential frontline triage instrument in obstetric, pediatric, and psychiatric primary care settings to facilitate prompt psychiatric referral and mitigate adverse maternal-neonatal outcomes^{2, 3}.

Etiology & Risk Factors

• Hormonal Fluctuations: Rapid postpartum withdrawal of circulating estrogens, progesterone, and placental corticotropin-releasing hormone precipitating neuroendocrine destabilization¹.
• Personal or Family Psychiatric History: Prior episodes of major depressive disorder, postpartum depression, bipolar spectrum disorders, or severe premenstrual dysphoric disorder^{1, 2}.
• Psychosocial Stressors: Inadequate social or partner support, financial instability, marital conflict, and unintended or complicated pregnancies^{3, 4}.
• Obstetric and Neonatal Complications: History of perinatal loss, traumatic delivery, emergency cesarean section, neonatal intensive care unit (NICU) admission, or infant congenital anomalies^{2, 3}.
• Endocrinopathies: Underlying or postpartum thyroid dysfunction (e.g., postpartum thyroiditis) mimicking or exacerbating depressive symptoms¹.

Pathophysiology

The pathophysiological framework underpinning perinatal depression involves complex neuroendocrine, genetic, and neurocircuitry alterations that manifest as elevated EPDS scores^{1, 6}. Following parturition, the abrupt decline in fetoplacental steroid hormones triggers disturbances in gamma-aminobutyric acid (GABA)ergic and serotonergic neurotransmission, destabilizing mood regulation^{1, 6}. Concurrently, activation of the hypothalamic-pituitary-adrenal (HPA) axis due to sleep deprivation and physical stressors results in sustained hypercortisolemia¹. Neuroimaging studies demonstrate functional uncoupling between prefrontal cortical regulatory regions and limbic structures such as the amygdala, leading to impaired emotional processing, heightened vulnerability to stress, and the emergence of anhedonic and anxious phenotypes captured by specific subscales of the EPDS^{6, 7}.

Clinical Presentation & Classic Clinical Signs

• History & Cardinal Symptoms: Patients present with persistent depressed mood, profound loss of interest or pleasure in usual activities (anhedonia), inappropriate guilt, feelings of worthlessness, psychic and somatic anxiety, panic symptoms, and intrusive thoughts regarding infant safety or self-harm^{1, 6, 7}.
• Physical Examination & Named Clinical Signs: General appearance may reveal psychomotor retardation or agitation, flat affect, tearfulness, and poor eye contact. Signs of extreme sleep deprivation and self-neglect are frequently observed without focal neurological deficits^{1, 2}.

Diagnostic Workup & Interpretation (Laboratory, Imaging & ECG/Pathology)

Staging, Classification & Clinical Scoring Systems

Differential Diagnosis

Management & Treatment Protocol

• Initial Stabilization & Resuscitation: Assess immediate safety, screen for suicidal or infanticidal ideation (particularly via evaluation of item 10), establish a secure care environment, and engage supportive family members or social services^{1, 2}.
• First-Line Medical / Pharmacological Therapy (with exact adult dosing): For moderate-to-severe depression, initiate selective serotonin reuptake inhibitors (SSRIs). Sertraline is preferred during lactation due to minimal breast milk transfer: start at 50 mg PO once daily, with titration by 25–50 mg increments every 1–2 weeks up to a maximum adult therapeutic dose of 200 mg PO daily. Alternative options include citalopram (10 mg PO daily titrated to 20–40 mg daily) or escitalopram (10 mg PO daily titrated to 20 mg daily)^{1, 2}.
• Psychotherapeutic Interventions: Evidence-based modalities including Cognitive Behavioral Therapy (CBT) and Interpersonal Psychotherapy (IPT), delivered individually or in structured group settings, serve as first-line treatment for mild-to-moderate depression or as adjunctive therapy with pharmacotherapy^{1, 3}.
• Surgical / Interventional Indications: Reserved for treatment-refractory severe major depressive episodes, catatonia, or acute suicidal crisis unresponsive to conventional pharmacotherapy and psychotherapy, where electroconvulsive therapy (ECT) or specialized neuromodulation may be indicated¹.

Complications & Prognosis

• Maternal Complications: Chronic unmanaged depressive illness, functional disability, relationship discord, increased risk of self-harm, suicide, and chronicity or recurrence in subsequent pregnancies^{1, 2}.
• Neonatal and Pediatric Sequelae: Impaired mother-infant bonding, insecure attachment styles, delayed cognitive and emotional development, and behavioral difficulties in offspring^{2, 3}.
• Prognosis: Favorable when identified early via systematic screening tools such as the EPDS and managed promptly with a multidisciplinary approach combining pharmacotherapy, psychotherapy, and robust social support^{1, 2, 3}.